Suppliers and packagers for gilotrif

gilotrif

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292	NDA	Boehringer Ingelheim Pharmaceuticals, Inc.	0597-0137-30	1 BOTTLE in 1 CARTON (0597-0137-30) / 30 TABLET, FILM COATED in 1 BOTTLE	2013-07-12
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292	NDA	Boehringer Ingelheim Pharmaceuticals, Inc.	0597-0137-90	1 BOTTLE in 1 CARTON (0597-0137-90) / 30 TABLET, FILM COATED in 1 BOTTLE	2013-07-12
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292	NDA	Boehringer Ingelheim Pharmaceuticals, Inc.	0597-0138-30	1 BOTTLE in 1 CARTON (0597-0138-30) / 30 TABLET, FILM COATED in 1 BOTTLE	2013-07-12

Suppliers for the Pharmaceutical Drug: Gilotrif (Afatinib)

Last updated: August 3, 2025

---

Introduction

Gilotrif (afatinib) is an oral targeted therapy developed by Boehringer Ingelheim for the treatment of non-small cell lung cancer (NSCLC) with specific epidermal growth factor receptor (EGFR) mutations. Since its approval by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), the drug's supply chain involves multiple stakeholders, including active pharmaceutical ingredient (API) manufacturers, formulation producers, and distribution partners. This report details the current landscape of suppliers involved in the manufacturing and supply of Gilotrif, highlighting their roles, geographic distribution, and potential supply chain implications.

---

Active Pharmaceutical Ingredient (API) Suppliers

1. Boehringer Ingelheim – Original API Manufacturer

Boehringer Ingelheim originally developed and co-marketed afatinib. The company maintains proprietary control over the core API manufacturing process, ensuring quality and supply continuity for branded Gilotrif. As a large-scale, global pharmaceutical company, Boehringer Ingelheim operates manufacturing facilities primarily in Europe and North America, with robust quality assurance systems compliant with international standards (ICH Q7, cGMP). Their vertically integrated supply chain underpins consistent API production, essential for maintaining product quality and regulatory compliance.

2. Contract Manufacturing Organizations (CMOs)

While Boehringer Ingelheim produces the API for Gilotrif, third-party CMOs play increasingly critical roles in API synthesis, especially due to market expansion and potential supply shortages. These CMOs often include:

• Zhejiang Hisun Pharmaceutical Co., Ltd., China: Known for producing APIs for various oncology drugs, Zhejiang Hisun offers API synthesis capabilities aligned with global GMP standards. Their strategic position in China allows for cost-effective manufacturing and volume scalability, though supply chain risks tied to geopolitical factors necessitate risk mitigation strategies.

• Jiangsu Hansoh Pharmaceutical Co., Ltd., China: An expanding player in API manufacturing with proven capacity for complex small molecules, including kinase inhibitors similar to afatinib.

• Dr. Reddy's Laboratories, India: Known for its extensive API manufacturing network, Dr. Reddy's supplies APIs for several targeted therapies. Their facilities adhere to stringent quality standards, serving both generic and branded markets.

These CMO suppliers provide flexibility in global supply, often supporting regional manufacturing needs, especially in Asia.

---

Formulation and Finished Dosage Form (FDF) Suppliers

1. Boehringer Ingelheim's Contract Facilities

As the innovator, Boehringer Ingelheim manages the formulation, packaging, and distribution logistics of Gilotrif through its own facilities, primarily located in Europe and North America. These facilities are equipped with advanced capabilities for tablet formulation, blister packing, and quality testing, adhering to the latest pharmaceutical standards (EU GMP, FDA cGMP).

2. Contract Manufacturing & Packaging Partners

Additional suppliers involved in the packaging process include:

• STM Swiss-based Contract Packaging Firms: Specialized in unit-dose packaging, ensuring stability and precise dosage delivery.

• Thermo Fisher Scientific: Provides serialization and supply chain serialization solutions to meet regulatory demands globally.

These partners ensure that Gilotrif reaches markets with the appropriate packaging and serialization compliant with regional regulations such as the Drug Supply Chain Security Act (DSCSA) in the US and Falsified Medicines Directive (FMD) in the EU.

---

Distribution Channels and Supply Chain Considerations

The distribution of Gilotrif is managed via global supply and logistics partners, including pharmaceutical wholesalers, specialty distributors, and pharmacy benefit managers (PBMs). Boehringer Ingelheim’s global supply chain networks facilitate distribution across North America, Europe, Asia-Pacific, and emerging markets.

Potential supply chain vulnerabilities include:

• API shortage risks: Due to geopolitical tensions, manufacturing disruptions, or raw material supply constraints, especially from high-volume Chinese and Indian API suppliers.

• Regulatory hurdles: Variations in regional regulations can delay manufacturing approvals or distribution, impacting availability.

• Logistics disruptions: The global nature of pharmaceutical supply chains exposes Gilotrif to risks from COVID-19-related disruptions, port closures, or transportation delays.

---

Key Players and Market Dynamics

Boehringer Ingelheim remains the primary and exclusive source of API and finished product for Gilotrif. The company's vertical integration and strategic partnerships with CMOs enable steady supply and regulatory compliance. However, the reliance on third-party API manufacturers in China and India introduces risks requiring active risk mitigation strategies, such as dual sourcing and regional manufacturing expansion.

Manufacturing Capacity Expansion: With increasing global demand for targeted therapies, Boehringer Ingelheim and its CMO partners are investing in expanding manufacturing capacity, including facility upgrades and process innovations, to ensure continuous supply.

Generic Competition and Market Entry: Although solely supplied by Boehringer Ingelheim for the branded product, the growing availability of generic afatinib formulations, produced by multiple Chinese and Indian companies, influences pricing and supply dynamics. However, proprietary formulations or manufacturing standards often restrict the use of generics in certain regulated markets.

---

Regulatory and Quality Assurance

Suppliers—both original and contract manufacturers—must adhere to stringent quality standards to meet regulatory requirements. API manufacturers are subject to inspections by agencies like the FDA, EMA, and other national authorities, which verify compliance with cGMP guidelines. The ongoing quality assurance processes include rigorous raw material testing, in-process controls, and stability testing for finished APIs and formulations.

Regulatory Compliance Impact:

Any deviation or interruption in API quality or production can lead to supply shortages. Contingency plans include maintaining stockpiles, qualifying multiple suppliers, and diversifying manufacturing locations.

---

Conclusion

The supply chain for Gilotrif predominantly hinges on Boehringer Ingelheim’s manufacturing infrastructure, supplemented by regional CMO partnerships primarily located in China and India for API supply, and Europe/US for formulation and packaging. The integrity of these supply channels is critical for maintaining consistent availability of Gilotrif across global markets.

The increasing dependency on Asian API manufacturers underscores the need for strategic risk management, including supply chain diversification, capacity expansion, and robust quality oversight.

---

Key Takeaways

• Primary API source: Boehringer Ingelheim, with support from Asian CMOs such as Zhejiang Hisun and Jiangsu Hansoh.
• Supply chain complexity: Managed via a mix of in-house manufacturing and regional CMOs, with global logistics partners ensuring distribution.
• Risks: Geopolitical factors, raw material shortages, and regulatory hurdles pose ongoing supply chain risks.
• Market sustainability: Capacity expansion and diversification of suppliers are vital to meet growing global demand.
• Regulatory importance: Continuous compliance with quality standards and proactive regulatory engagement are crucial for uninterrupted supply.

---

FAQs

1. Who are the main suppliers of the API for Gilotrif?
Boehringer Ingelheim is the primary API manufacturer, supported by Asian CMOs such as Zhejiang Hisun and Jiangsu Hansoh, which produce afatinib to meet global demand.

2. How does the supply chain ensure quality and regulatory compliance?
Suppliers adhere to international cGMP standards, with regular inspections and quality audits conducted by regulatory bodies like the FDA and EMA, ensuring high-quality API and finished product manufacturing.

3. Are there risks associated with reliance on Chinese and Indian API manufacturers?
Yes, geopolitical tensions, supply disruptions, or raw material shortages could impact API supply. Diversification and capacity expansion mitigate these risks.

4. How does Boehringer Ingelheim manage formulation and distribution?
Through its own facilities and contracted packaging partners across Europe and North America, with advanced logistics ensuring compliance and timely delivery across markets.

5. Are generic versions of afatinib available, and how do they impact the supply chain?
Generic afatinib is produced by several Chinese and Indian manufacturers, increasing competition and affecting market prices, but original formulations benefit from established regulatory pathways.

---

References:

1. Boehringer Ingelheim official website. https://www.boehringer-ingelheim.com.
2. FDA Drug Approvals Database. Gilotrif (afatinib) NDA 204792.
3. European Medicines Agency (EMA). Gilotrif Summary of Product Characteristics (SmPC).
4. Market research reports on pharmaceutical API manufacturing.
5. Industry publications on global API manufacturing capacity and risks.